Adam Davidson, CEO of Trident Royalties, discusses offtake milestones and catalysts to boost FY24. Watch the video here.
Oops meant to also post
https://www.probi.com/annual-report/en/
mol
Stephen has mentioned Probi a number of times over the years so I thought I would just do a bit of doodling
and their relationship with clasado biosciences seems to be going from strength to strength
https://www.probi.com/search/?query=clasado
I recognise at least three of the team at Clasado
https://clasado.com/corporate/
just a bit of info
mol
A further US patent granted 20 February 2024
https://patents.justia.com/patent/11903979#history
albeit doesn't at moment seem to have been assigned to pbx though i'm no expert in these matters and it is not the first according to list below
https://patents.justia.com/inventor/stephen-patrick-o-hara
mol
We now have the undernoted
https://optibiotix.com/wp-content/uploads/2024/04/Slimbiome-Soup.pdf
in addition to
https://optibiotix.online/products/snacksmart-soups
nothing like different marketing messages ............
who is responsible for this i wonder?
perhaps i'm being a bit harsh as one is under snacksmart and the other isn't
nah - lol
mol
It would be very helpful to have a similar presentation this year - especially as Graham now in position - prior to year end audited results generally late May/June
https://www.walbrookpr.com/docs/librariesprovider48/default-document-library/investors/optibiotix---investor-presentation-may-2023.pdf
mol
Sbtx a very useful addition afterwards as it basically became a vehicle to raise funds to continue the main thrust which i don't think even Stephen had anticipated nor intended at outset of its separate existence
mol
Oh come on martinu we've only had 10 years to date from listing (12 in total)
OptiBiotix has established a pipeline of microbiome modulators that impact on energy harvest, appetite
suppression, and lipid and cholesterol management. The development pipeline is fuelled by its proprietary
platform technologies including:
OptiScreen ® : A proprietary high throughput screening and optimisation technology platform designed to
identify microbes within the human microbiome with metabolic pathways which can interact with human
physiological processes and bring health benefits.
OptiBiotic ® : A proprietary platform technology which generates novel compounds and screens them for
their ability to modulate the human microbiome and its microbial end products. This creates the potential to
influence host metabolism and physiology for the prevention and management of disease.
These platforms have been validated in development programmes which have established a pipeline of
compounds which modulate the human microbiome to bring health benefits, including:
● 3 microbial strains which have demonstrated the ability to reduce cholesterol by 71 per cent.,
78 per cent., and 82 per cent., respectively, in laboratory studies;
● An ingredient formulation scientifically formulated by its international key opinion leaders to support
and sustain weight loss in overweight and obese patients. The formulation has been developed so
that components act differently in both their mechanism and site of action; and
● A compound which can selectively enhance the growth of specific microbial species in the human
microbiome. Selectively enhancing specific microbial species creates the capability to modify the human
microbiome specific to health needs.
In summary, the research programme to be followed by OptiBiotix is expected to include:
Cholesterol and lipid management product
The three strains shown to reduce cholesterol in the laboratory will be tested to confirm the absence of
antimicrobial resistance and virulence factors, and to assess gut survivability and manufacturing scale up
capability. On completion of these studies the product will be tested in a human nutritional study to assess
the ability of the product to reduce human cholesterol in at risk populations. Following analysis of the data,
the results will be published in clinical journals.
Microbiome modulator generation and screening
High throughput screening of numerous microbial strains will be used to identify strains with the enzymic
capability of producing novel sugars. Microbial strains with high enzymic activity will be selected and reaction
conditions created to produce sufficient novel sugars for an assessment of their commercial potential,
including:
● identification of novel non-digestible sugars with a sweet taste, low calorific value, and an insulin
independent metabolism with commercial potential as sugar substitutes;
lpldl slimbiome and sweetbiotix
sbtx a
A recent article written by Stephen
https://nmc-magazine.com/is-there-a-more-sustainable-approach-to-weight-loss-than-injectable-drugs/
i'm back to doing a bit of doodling
bw all
mol
Website now accessible
and i note as of today
Shares In Issue
As at 28 March 2024, the number of shares in issue was 97,943,161.
Significant Shareholders
As at 29 April 2024, significant shareholders that hold more than 3% of the share capital of OptiBiotix Health Plc, and shareholdings of any other directors are detailed below:
Number Ordinary Shares %
Stephen O'Hara (Director) 10,212,986 10.43
Finance Yorkshire Seedcorn Fund (FYSCF) 5,713,314 5.83
Stephen O'Hara holds 6,099,135 shares under Option
Directors' Shareholders
Number Ordinary Shares %
Stephen O'Hara (Director) 10,212,986 10.43
Neil Davidson (Director) 503,000 0.51
Sean Christie (Director) 150,000 0.15
Graham Myers (Director) 125,000 0.13
So FYSF have reduced their holding by 1375000 between 16 Feb and 29 Apr 24
mol
As opposed to tick tock
https://www.tiktok.com/@optibiotix
i'm no expert re tiktok/instagram/facebook etc
but the numbers following etc the above are pathetic after all this time
and i cannot access the optibiotix website on firefox since my return from holiday
The page you are trying to view cannot be shown because the authenticity of the received data could not be verified.
Please contact the web site owners to inform them of this problem.
nothing on boots either
jees some things never change with opti
as i have previously noted - i'm giving him to end of this year - at the latest - tick tock
mind not that he will give a ........... and nor should he in response to a BB and his latest placing to keep the lights on
nevermind the gloss put on it within the rns
mol
I Have a Dream, a song to sing
To help me cope, with anything
If you see the wonder, of a fairy tale
You can take the future, even if you fail
I believe in angels
Something good in everything I see
I believe in angels
When I know the time is right for me
I'll cross the stream, I Have a Dream
I Have a Dream, a fantasy
To help me through, reality
And my destination, makes it worth the while
Pushin' through the darkness, still another mile
Didn't I would be tempted to post the above and obvious to the thread
But couldn’t help myself lol
mol
Recent Developments
Last Updated: 22/03/2024
SBTX accompanied their half year results on 22 March with an interesting Investor Meet presentation, which can be found on the site, and featuring alongsideCEO Stuart Ashman the CFO, the Sederma (Croda) trials director and the CEO of the recent Dematonics acquisition. Revenues remain low (£107,000 + 38%), but they have signed up a new partner to market their psoriasis product via Amazon. Key points from the RNS and presentation included:
Final clinical trial stage to complete May/June of 5 year work with Sederma- now not binary, but a question of whether they can launch with clinical claims and correspondingly higher price point or not.
Marketing deal for Axisbiotix with World Products via Amazon, who they have got to know through Dermatonics acquisition
Dermatonics has high but as yet unquantified hopes for sales in Asia via the Umesh Modi group.
They are looking at cutting raw material costs.
Will launch an acne product this year. The data for the 220 person study backing this up was released in an RNS in February.
Unwinding CLN arrangement but say they now have potential of alternative funding lines for other acquisitions.
CEO and CFO have taken 20% pay cut after criticism of their pay.
Operating loss was £1.39m vs £1.35m, cash at end December £2.84m vs £1.31m at end June, after a £3.3m gross placing in November.
SBTX announced a new six-month research project (“Epidem”) at Manchester University on 18 March, which they are co-funding, to look at the use of non-pathogenic bacteria in wound healing. It will be run by two professors. At the same time they announced that their (Manchester-based) CSO, Professor Cath O’Neill, is stepping back from her role to “return to academia” but will remain as a Scientific adviser.
mol
By another
Investment Case
SkinBioTherapeutics is potentially well positioned to be a leader in the skin health probiotic market. The company has two active developments arms: SkinBiotix is a partnership with Croda in developing new anti-ageing products (the collaboration contract was extended for 12 months in October). AxisBiotix is a food supplement to treat psoriasis sufferers which was introduced to the market through a pilot launch both in the UK and the USA in November 2022. The company is targeting significant markets with its lead opportunities but so far has not yet made material progress, so positive consumer reviews are encouraging. As well as psoriasis and cosmetics applications, SBTX has in the past referred to other potential applications for their formulations, including wound care (Medbiotix), oral health and acne – where progress on the patient study has now been reported.
The Direct-to-Consumer launch of AxisBiotix in late 2021 did not initially generate the hoped-for sales in the UK and the company acknowledged that it needed to change its marketing strategy and is looking for a global distributor. Launches in Europe are being done directly by the company. The timing of progress with Croda is very reliant on Croda’s internal processes. SBTX remains a very small company tackling very large categories and success would be transformative but is dependent on take-up by larger companies.
Brokers Cavendish has June 2024 forecasts of £1.1m revenues (so a big ramp up from H1, but starting to show the benefit of Dermatonics), £2.4m loss at EBITDA level and net debt of £600,000. For the next year the key will be for when and to what extent royalties start flowing from the Croda relationship. Cavendish revised its numbers after the Dermatonics announcement to a target of 48p, slightly down taking into account the new convertible note. As things stand this seems very distant and the company will need to provide clarity on future funding, as well as meeting the now heightened expectations of a launch with Croda.
That would be the 5m loan note announced on 25 Jan 2024 only for this on 28 Feb 24 - what's that under 5 weeks
To date, the Company has drawn a total of £1,600,000 under the Facility. The Board of SkinBioTherapeutics has today provided formal notice to CLG Capital LLC (CLG) (and by proxy Macquarie) that it will not utilise the reminder of the £5m Facility. The Board is in negotiations with the noteholders to discuss timing and rate of conversion and subsequent selling of stock.
Stuart Ashman, CEO of SkinBioTherapeutics said: "We met the CLG team today and have come to an amicable agreement around the Facility and next steps. We believe this is the right decision for the Company. In the meantime, we are very busy integrating the recently acquired Dermatonics, the accelerated Modi/Dermatonics product launch in the Asia, Middle East and Africa regions, and completing the participant study for the acne programme which has generated very positive interim results. We anticipate further updates in the coming weeks in the lead up to the HY results in March."
whilst as Bazza notes on 22nd March the cln was the best option.........
jees if any further evidence was ever needed
the cln note is not the only thing that overhangs this company
mol
On sale from 23 Feb 2024
https://www.amazon.co.uk/MuscleTech-NitroTech-Weightloss-Servings-Chocolate/dp/B0CW9Y256T/ref=sr_1_8?dib=eyJ2IjoiMSJ9.j2lnQLFdow5hZMjAS0VapCW7FprAvMaME9nY1JiRN4HvrT781gvZsEgS7M6k8dmtsO-TxY7Y589UwAM7D80WZnQZqdpvJTZcQOKnrE58YFmtipjeEXfKCyit0qWOM78_mnAZ504hFCudnRdlMMWKxnp5rQEXmlfh73xirR3Xcyvpv6CfGEporeBmt6gclph5zwx4JSvUj43aTVM85t3H1IVRssG3G6_7ze1OAu8219oEd_S3dfyFnOnFWFpoXl-hlnN2s8LQYrOXgOuV8a4znoOOP-rJq-gNS3CPn2RMe0U.l7IBC4HFcLPQmKexMIM_OJsAmwZ0bGiMPcsNA9ctAT0&dib_tag=se&keywords=nitrotech+ripped+protein&qid=1711647399&sr=8-8
and
https://www.amazon.co.uk/MuscleTech-NitroTech-Protein-Weightloss-Servings/dp/B0CW9Y3LB4/ref=sr_1_10?dib=eyJ2IjoiMSJ9.j2lnQLFdow5hZMjAS0VapCW7FprAvMaME9nY1JiRN4HvrT781gvZsEgS7M6k8dmtsO-TxY7Y589UwAM7D80WZnQZqdpvJTZcQOKnrE58YFmtipjeEXfKCyit0qWOM78_mnAZ504hFCudnRdlMMWKxnp5rQEXmlfh73xirR3Xcyvpv6CfGEporeBmt6gclph5zwx4JSvUj43aTVM85t3H1IVRssG3G6_7ze1OAu8219oEd_S3dfyFnOnFWFpoXl-htmH9UvsX5v_yggSDq5HVnlrEqoHkoMLXVZnm3Bf-fGI.QAePYc7xczEiBqffbdXuz7YDIQOSSlw0c8m3CjlDeZg&dib_tag=se&keywords=nitrotech+ripped+protein&qid=1711647780&sr=8-10
there may be other flavours but you get the gist at least on sale in europe
nowt so far re boots online - as far as i can decipher
mol